Morton DL - Search Results

1

Characterization and augmentation of CD4+ cytotoxic T cell lines against melanoma.

Morisaki T, Morton DL, Uchiyama A, Yuzuki D, Barth A, Hoon DS. Morisaki T, et al. Among authors: morton dl. Cancer Immunol Immunother. 1994 Sep;39(3):172-8. doi: 10.1007/BF01533383. Cancer Immunol Immunother. 1994. PMID: 7923247 Free PMC article.

2

Interleukin 4 receptor expression and growth inhibition of gastric carcinoma cells by interleukin 4.

Morisaki T, Yuzuki DH, Lin RT, Foshag LJ, Morton DL, Hoon DS. Morisaki T, et al. Among authors: morton dl. Cancer Res. 1992 Nov 1;52(21):6059-65. Cancer Res. 1992. PMID: 1394231

3

Induction of CD4+ cytotoxic T cells by sensitization with allogeneic melanomas bearing shared or cross-reactive HLA-A.

Hayashi Y, Hoon DS, Park MS, Terasaki PI, Foshag LJ, Morton DL. Hayashi Y, et al. Among authors: morton dl. Cell Immunol. 1992 Feb;139(2):411-25. doi: 10.1016/0008-8749(92)90082-z. Cell Immunol. 1992. PMID: 1733512

4

Modulation of human melanoma cells by interleukin-4 and in combination with gamma-interferon or alpha-tumor necrosis factor.

Hoon DS, Banez M, Okun E, Morton DL, Irie RF. Hoon DS, et al. Among authors: morton dl. Cancer Res. 1991 Apr 15;51(8):2002-8. Cancer Res. 1991. PMID: 1901239

5

Interleukin 4 alone and with gamma-interferon or alpha-tumor necrosis factor inhibits cell growth and modulates cell surface antigens on human renal cell carcinomas.

Hoon DS, Okun E, Banez M, Irie RF, Morton DL. Hoon DS, et al. Among authors: morton dl. Cancer Res. 1991 Oct 15;51(20):5687-93. Cancer Res. 1991. PMID: 1913686

6

Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide.

Hoon DS, Foshag LJ, Nizze AS, Bohman R, Morton DL. Hoon DS, et al. Among authors: morton dl. Cancer Res. 1990 Sep 1;50(17):5358-64. Cancer Res. 1990. PMID: 2143687 Clinical Trial.

7

A decapeptide (Gln-Asp-Leu-Thr-Met-Lys-Tyr-Gln-Ile-Phe) from human melanoma is recognized by CTL in melanoma patients.

Morioka N, Kikumoto Y, Hoon DS, Morton DL, Irie RF. Morioka N, et al. Among authors: morton dl. J Immunol. 1994 Dec 15;153(12):5650-8. J Immunol. 1994. PMID: 7527447

8

Cytotoxic T cell recognition of a human melanoma derived peptide with a carboxyl-terminal alanine-proline sequence.

Morioka N, Kikumoto Y, Hoon DS, Morton DL, Irie RF. Morioka N, et al. Among authors: morton dl. Mol Immunol. 1995 Jun;32(8):573-81. doi: 10.1016/0161-5890(95)00020-f. Mol Immunol. 1995. PMID: 7541891

9

The role of adjuvant therapy in melanoma management.

Barth A, Morton DL. Barth A, et al. Among authors: morton dl. Cancer. 1995 Jan 15;75(2 Suppl):726-34. doi: 10.1002/1097-0142(19950115)75:2+<726::aid-cncr2820751417>3.0.co;2-r. Cancer. 1995. PMID: 7805001 Review.

10

Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen.

Hoon DS, Yuzuki D, Hayashida M, Morton DL. Hoon DS, et al. Among authors: morton dl. J Immunol. 1995 Jan 15;154(2):730-7. J Immunol. 1995. PMID: 7814879

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

686 results

Search Page

Filters